ph365 original

ph365 original Ministers said an extra £15 million will be made available for supply chain businesses and workers affected by changes at Tata’s Port Talbot site in south Wales. Welsh Secretary Jo Stevens said the move means a fund to support businesses across Wales heavily reliant on Tata steel will be increased to £30 million. She also announced that more businesses will be able to apply for the funds, and the value of individual grants is increasing to up to £250,000 for businesses to invest in equipment, property, technology. The Government said there has been “significant demand” on the existing funding, with almost 40 businesses employing 2,000 people having begun the application process. Grants worth millions of pounds are expected to be released in the new year. The increase in funding is in anticipation of more people leaving Tata in early 2025 through the company’s voluntary redundancy scheme. Ms Stevens said: “This Government is acting decisively to support workers and businesses in Port Talbot. “We are doubling the funding available to businesses and workers and widening access to grants to ensure we support as many people as possible. “In just four months we have announced more than £40 million in investment. We said we would back workers and businesses affected by the transition at Port Talbot and we are doing exactly that. “While this remains a very difficult time for Tata workers, their families and the community, we are determined to support workers and businesses in our Welsh steel industry, whatever happens.”

UnitedHealth projects 2025 operating cash flow below estimatesThe ( ) share price is under pressure on Monday morning. At the time of writing, the giant's shares are down 1.5% to $30.68. Why is the ANZ share price falling? Investors have been selling the company's shares this morning after it a change of leadership. According to the release, ANZ's CEO Shayne Elliott is retiring after nine years in the role. He will be handing over the reins at the start of July next year then remain available until the end of September to support his replacement. Commenting on his exit, Elliott said: Leading ANZ over the last nine years has been the highlight of my career. I'm proud to be leaving the bank in such a strong position, particularly the work we have done to simplify the business, transforming institutional into one of the world's best and preparing our retail bank for the future. The recent Suncorp Bank acquisition will also benefit ANZ for years to come. New leader appointed The good news is that the bank has already found its new leader. It revealed that Nuno Matos will become its new CEO on 3 July 2025 on a $2.5 million a year deal. The release notes that Matos has 30 years' experience across retail, commercial, and wholesale banking. He was most recently CEO of Wealth and Personal Banking at where he was responsible for 87,000 employees serving approximately 40 million customers across 35 markets. He also held senior roles including CEO of HSBC Bank plc and HSBC Europe, where he oversaw the transformation of its European business. He has also previously served as CEO Mexico, one of HSBC's largest markets, and Regional Head of Retail Banking in Latin America. Prior to his time at HSBC, Matos was the Global Head of Consumer in its Retail and Commercial Division at . Commenting on the appointment, ANZ's chair, Paul O'Sullivan, said: We are very pleased an international banker of Nuno's calibre and extensive experience will be joining ANZ as our new Chief Executive to lead the execution of our strategy. O'Sullivan also revealed that the appointment has been in the works for some time. He adds: Nuno's appointment is the culmination of long-term systematic work by the Board on leadership succession. Having assessed multiple external and internal candidates, we know Nuno is the right person to build on the transformation already well progressed under the leadership of Shayne and his team. Critically, Nuno has led several bank business, risk and technology transformations, which will be a significant benefit as we prepare to scale the migration of customers, including those from Suncorp Bank, across to ANZ Plus as well as supporting our focus on non-financial risk. The bank's chair also believes it will be business as usual for the bank. He notes that "bank is in a strong position and this orderly leadership transition ensures ANZ will continue to deliver for customers, shareholders and staff in the years to come."

The Detroit Lions have equaled the franchise record for most consecutive victories and stand alone atop the NFC standings. They still have plenty of obstacles to clear to remain at that perch. Even the NFC North remains up for grabs and they'll try to create a little more separation when they host the Green Bay Packers on Thursday night. The Lions (11-1), who have won 10 straight, haven't been able to shake free from Minnesota (10-2) or Green Bay (9-3). Detroit will host Minnesota, which has won five straight, in the regular-season finale next month. The Packers have remained in contention by winning seven of their last eight, with the only loss coming at the hands of the Lions. Detroit opened up a 21-point lead early in the third quarter and held on for a 24-14 victory. Lions coach Dan Campbell says the fun really begins now. "The best part of all of this -- we're in playoff football right now, that's where we're at," he said. "We're in December, and our schedule says that. Man, we play tough opponent after tough opponent -- we've got plenty coming up. So, man, this is the type of stuff that you live for and it's also the type of stuff that gets you ready for the tournament. "So, yeah, we're a resilient bunch and nothing's going to change that. We've just got to worry about the one in front of us." Detroit is coming off a 23-20 win over Chicago on Thanksgiving Day in which it nearly blew a 16-point lead. The Bears' poor clock management cost them an opportunity to send the game into overtime and led to coach Matt Eberflus' firing. The Lions have been hit with a wave of injuries, particularly on the defensive side. They signed four players over the past week to fortify their depth. "I know the elephant in the room is all the injuries that have happened with us on the defensive side," defensive coordinator Aaron Glenn said. "Our personnel staff does a really good job of acquiring players that fit exactly who we are. I would say this, it's not the playbook that's the most important thing for these guys to come in and learn. It's the style of play that we have and that's easy to learn." Jared Goff has thrown for six touchdowns and zero interceptions in the past three games after tossing five picks against the Houston Texans on Nov. 10. The Packers also played on Thanksgiving, defeating Miami 30-17. Green Bay opened up a 24-3 halftime lead as Jordan Love threw two touchdown passes to Jayden Reed. Now the Packers face a Detroit team that has defeated them in five of the last six meetings. "With most good teams, they play the game the right way," Green Bay coach Matt LaFleur said. "Certainly, Detroit's been doing that for a couple years now. That's who they are and that's who we are as well. It should be a great game on Thursday night." The Packers might have to win via a shootout, considering the Lions are averaging a league-best 31.9 points per game (Green Bay ranks eighth at 26.5). Stopping the running game will be key, according to LaFleur. "They're two very dynamic backs. (David) Montgomery, he's going to beat you up physically and the other guy (Jahmyr Gibbs), you've got to try to corral because he can take it the distance," he said. "Jared (Goff) is playing at an MVP level, so they've got a really potent offense." Lions offensive tackle Taylor Decker (knee) and three defensive linemen -- DJ Reader (shoulder), Josh Paschal (knee) and Levi Onwezurike (hamstring) -- didn't practice on Tuesday. Offensive guard Elgton Jenkins (knee), Linebacker Edgerrin Cooper (hamstring) and cornerback Corey Ballentine (knee) missed the Packers' practice. --Field Level MediaWall Street inches higher to set more records

More funds to support steel workers and businesses

NoneMARTINSBURG — Berkeley County Schools recently held its Sensory Santa event on Wednesday evening at Rosement Elementary School, where families had a safe place to get photos and participate in a fun Christmas tradition. For two years, Berkeley County Schools has partnered with Birth to Three to create this special event and reach out into the community. Birth to Three is a statewide system of services designed to help children with development delays or who are at risk for a delay. It has partnered with Berkeley County Schools for several events to better serve the community and reach more families in need. Terri Hickerson, parent resource and technology support coordinator with Berkeley County Schools, and Emily Church, service coordinator at Birth to Three, worked together to create this event for people in the community. “With the rush of the season and everyone is so busy, we decided to do Sensory Santa earlier in the month,” Hickerson said. “We do it so children that can’t handle the lights, sounds and crowds during other events like this can have an environment that fits their needs.” In addition to meeting Santa and taking pictures, kids also participated in sensory activities, enjoyed some Christmas treats and watched a movie playing throughout their visit. Each child left with a goodie bag filled with candy and other special trinkets, a Santa hat and a book of their choice. Birth to Three received the books as donations to give to kids, while also sharing its contact information to let more people know who they are and what they do. This year, it had around 42 families sign up, almost twice as many as last year. However, Hickerson shared that it isn’t about how many families participate. If the kids who do come have a good time, then she considers the event a success. “I love seeing the parents, because they are always so appreciative to have a place to bring their kids,” Hickerson said. “They are always so thankful. Even if their kid has a hard time, there is no judgement here.” If children got overwhelmed anytime during their visit, the school prepared a separate room for them to get away and calm down. Hickerson shared that Principal Erica Propst and the rest of the Rosemont Elementary School staff have been very generous by letting the two groups borrow the space to make this event happen. By having a centralized location, Hickerson and Church hope to have a better outreach and provide more opportunities for families with special-needs children.

WASHINGTON (Reuters) - The U.S. Senate on Wednesday passed the National Defense Authorization Act, or NDAA, which sets policy for the Pentagon, for the 64th straight year, sending it to the White House for President Joe Biden's signature. Because it is one of the few major bills that becomes law every year, lawmakers use the NDAA as a vehicle for a range of initiatives, some more directly related to the military than others. Here is a look at some notable provisions of the 1800-page Fiscal 2025 NDAA. WHAT IS THE TRANSGENDER PROVISION? The bill bans the military health program, TRICARE, from covering some gender-affirming care for the transgender children of service members if it could risk sterilization, a provision that caused some Democrats to vote no in the Senate and in the House. The measure was denounced by groups that support transgender rights, but Democrats who backed the bill said the provision was far more narrow than some Republicans had wanted. For example, during negotiations on this year's bill, some Republicans had pushed to ban TRICARE from covering gender-affirming care for adults. President-elect Donald Trump's Republicans have made opposition to the rights of transgender people a focus of so-called "culture war" politics, using it successfully as a wedge issue during the 2024 U.S. elections. COUNTERING CHINA, BOLSTERING TAIWAN The NDAA steers resources toward countering China, seen as the biggest geopolitical threat to the United States. Among other things, the bill authorizes $300 million to help Taiwan acquire capabilities from anti-ship missiles and radars to coastal and missile defense, and measures to enhance diplomatic and economic backing for Taiwan. It also includes new restrictions on China and Chinese businesses, including requiring reports on China's economic outlook, biotechnology industry and synthetic opioids. The bill also extends bans on the military purchasing Chinese products, adding bans on drone technology as well as garlic in military commissaries. MIDDLE EAST The measure authorizes $500 million for U.S.-Israel missile defense, including funds for Israel's Iron Dome, David's Sling and Arrow systems. It also increases and expands to $80 million from last year's $50 million authorization for U.S.-Israel anti-tunneling cooperation. And it requires the Secretary of Defense and director of the Defense Intelligence Agency to provide Israel with defense intelligence and support of Israel's pursuit of Hamas and the capture or killing of Hamas officials. QUALITY OF LIFE AND PAY RAISES FOR THE TROOPS The NDAA authorizes an unusually high 14.5% pay increase for the lowest-ranking troops, and 4.5% for the rest of the force, recognizing that many military families have been forced to rely on food stamps and other forms of public assistance to make ends meet. The bill also authorizes $3 billion to improve military housing, and it will expand child care benefits, which military leaders had described as an obstacle toward recruitment. (Reporting by Patricia Zengerle; editing by Diane Craft)

WASHINGTON — Donald Trump said he can’t guarantee that his promised tariffs on key U.S. foreign trade partners won’t raise prices for American consumers and he suggested once more that some political rivals and federal officials who pursued legal cases against him should be imprisoned. The president-elect, in a wide-ranging interview with NBC’s “Meet the Press” that aired Sunday, also touched on monetary policy, immigration, abortion and health care, and U.S. involvement in Ukraine, Israel and elsewhere. Trump often mixed declarative statements with caveats, at one point cautioning “things do change.” A look at some of the issues covered: Trump hems on whether trade penalties could raise prices Trump has threatened broad trade penalties, but said he didn’t believe economists’ predictions that added costs on those imported goods for American companies would lead to higher domestic prices for consumers. He stopped short of a pledge that U.S. an households won’t be paying more as they shop. “I can’t guarantee anything. I can’t guarantee tomorrow,” Trump said, seeming to open the door to accepting the reality of how import levies typically work as goods reach the retail market. That’s a different approach from Trump’s typical speeches throughout the 2024 campaign, when he framed his election as a sure way to curb inflation. In the interview, Trump defended tariffs generally, saying that tariffs are “going to make us rich.” He has pledged that, on his first day in office in January, he would impose 25% tariffs on all goods imported from Mexico and Canada unless those countries satisfactorily stop illegal immigration and the flow of illegal drugs such as fentanyl into the United States. He also has threatened tariffs on China to help force that country to crack down on fentanyl production. ”All I want to do is I want to have a level, fast, but fair playing field,” Trump said. Trump suggests retribution for his opponents while claiming no interest in vengeance He offered conflicting statements on how he would approach the justice system after winning election despite being convicted of 34 felonies in a New York state court and being indicted in other cases for his handling of national security secrets and efforts to overturn his 2020 loss to Democrat Joe Biden. “Honestly, they should go to jail,” Trump said of members of Congress who investigated the Capitol riot by his supporters who wanted him to remain in power. The president-elect underscored his contention that he can use the justice system against others, including special prosecutor Jack Smith, who led the case on Trump’s role in the siege on Jan. 6, 2021. Trump confirmed his plan to pardon supporters who were convicted for their roles in the riot, saying he would take that action on his first day in office. As for the idea of revenge driving potential prosecutions, Trump said: “I have the absolute right. I’m the chief law enforcement officer, you do know that. I’m the president. But I’m not interested in that.” At the same time, Trump singled out lawmakers on a special House committee who had investigated the insurrection, citing Rep. Bennie Thompson, D-Miss., and former Rep. Liz Cheney, R-Wyo. “Cheney was behind it ... so was Bennie Thompson and everybody on that committee,” Trump said. Asked specifically whether he would direct his administration to pursue cases, he said, “No,” and suggested he did not expect the FBI to quickly undertake investigations into his political enemies. But at another point, Trump said he would leave the matter up to Pam Bondi, his pick as attorney general. “I want her to do what she wants to do,” he said. Such threats, regardless of Trump’s inconsistencies, have been taken seriously enough by many top Democrats that Biden is considering issuing blanket, preemptive pardons to protect key members of his outgoing administration. Trump did seemingly back off his campaign rhetoric calling for Biden to be investigated, saying, “I’m not looking to go back into the past.” Swift action on immigration is coming Trump repeatedly mentioned his promises to seal the U.S.-Mexico border and deport millions of people who are in the U.S. illegally through a mass deportation program. “I think you have to do it,” he said. He suggested he would try to use executive action to end “birthright” citizenship under which people born in the U.S. are considered citizens — although such protections are spelled out in the Constitution. Asked specifically about the future for people who were brought into the country illegally as children and have been shielded from deportation in recent years, Trump said, “I want to work something out,” indicating he might seek a solution with Congress. But Trump also said he does not “want to be breaking up families” of mixed legal status, “so the only way you don’t break up the family is you keep them together and you have to send them all back.” Trump commits to NATO, with conditions, and waffles on Putin and Ukraine Long a critic of NATO members for not spending more on their own defense, Trump said he “absolutely” would remain in the alliance “if they pay their bills.” Pressed on whether he would withdraw if he were dissatisfied with allies’ commitments, Trump said he wants the U.S. treated “fairly” on trade and defense. He waffled on a NATO priority of containing Russia and President Vladimir Putin. Trump suggested Ukraine should prepare for less U.S. aid in its defense against Putin’s invasion. “Possibly. Yeah, probably. Sure,” Trump said of reducing Ukraine assistance from Washington. Separately, Trump has called for an immediate ceasefire. Asked about Putin, Trump said initially that he has not talked to the Russian leader since Election Day last month, but then hedged: “I haven’t spoken to him recently.” Trump said when pressed, adding that he did not want to “impede the negotiation.” Trump says Powell is safe at the Fed, but not Wray at the FBI The president-elect said he has no intention, at least for now, of asking Federal Reserve Chairman Jerome Powell to step down before Powell’s term ends in 2028. Trump said during the campaign that presidents should have more say in Fed policy, including interest rates. Trump did not offer any job assurances for FBI Director Christopher Wray, whose term is to end in 2027. Asked about Wray, Trump said: “Well, I mean, it would sort of seem pretty obvious” that if the Senate confirms Kash Patel as Trump’s pick for FBI chief, then “he’s going to be taking somebody’s place, right? Somebody is the man that you’re talking about.” Trump is absolute about Social Security, not so much on abortion and health insurance Trump promised that the government efficiency effort led by Elon Musk and Vivek Ramaswamy will not threaten Social Security. “We’re not touching Social Security, other than we make it more efficient,” he said. He added that “we’re not raising ages or any of that stuff.” He was not so specific about abortion or his long-promised overhaul of the Affordable Care Act. On abortion, Trump continued his inconsistencies and said he would “probably” not move to restrict access to the abortion pills that now account for a majority of pregnancy terminations, according to the Guttmacher Institute, which supports abortion rights. But pressed on whether he would commit to that position, Trump replied, “Well, I commit. I mean, are — things do — things change. I think they change.” Reprising a line from his Sept. 10 debate against Vice President Kamala Harris, Trump again said he had “concepts” of a plan to substitute for the 2010 Affordable Care Act, which he called “lousy health care.” He added a promise that any Trump version would maintain insurance protections for Americans with preexisting health conditions. He did not explain how such a design would be different from the status quo or how he could deliver on his desire for “better health care for less money.”

Donald Trump aides contact Google, Meta, Snap over online drug sales: ReportNoneAP News Summary at 6:20 p.m. EST

Shawna Papale appointed president of Mohawk Valley EDGESouth Dakota State QB Mark Gronowski to enter portal, keep eye on draft

WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here . Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment landscape for patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF). The event will focus on Tectonic’s lead program, TX45, an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in patients with Group 2 PH-HFpEF in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study. A live question and answer session will follow the formal presentations. About the Key Opinion Leaders: Professor John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP (London) Professor Teerlink is Professor of Medicine at the University of California San Francisco (UCSF). After graduating from Swarthmore College with a Religion major, he received an MD from Harvard Medical School and completed his Internal Medicine residency and Cardiovascular Medicine fellowship at UCSF, as well as post-doctoral fellowships in Cardiovascular pharmacology (Hoffman-LaRoche; Basel, Switzerland), echocardiography (UCSF) and heart failure (UCSF-affiliated hospital). He is actively involved in the design and execution of many heart failure clinical trials, serving on endpoint, data monitoring, steering and executive committees for numerous international studies investigating a variety of new pharmacologic therapies, as well as stem cell and gene therapies, diagnostic modalities and other devices. He was the lead clinical investigator for the serelaxin development program, serving as Principal Investigator for Pre-RELAX-AHF, RELAX-AHF, RELAX-AHF-2 and RELAX-Repeat, and as a steering committee member for RELAX-AHF-Asia. Dr. Teerlink has served on the US FDA Cardiovascular and Renal Drug Advisory Committee, as well as on other FDA drug, device, diagnostics, and vaccine panels and serves as a consultant on pre-clinical and clinical development programs in multiple areas of cardiology, as well as in non-cardiovascular indications. Dr. Teerlink was a founding physician member of the American Association of Heart Failure Nurses and is a Past President of the Heart Failure Society of America. He was an Associate Editor for the Journal of Cardiac Failure, Guest Editor-in-Chief and Associate Editor for JACC: Heart Failure, and is a clinical scholar presenting many lectures and over 300 publications, including a chapter on Acute Heart Failure in Braunwald’s Heart Disease textbook. He was profiled in The Lancet as an internationally recognized leader in heart failure. Raymond L. Benza, MD, FACC, FAHA, FACP Dr. Benza is a Professor and System Director of Pulmonary Hypertension at the Icahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital. He is a fellow of the American College of Physicians, the American Heart Association Council on Clinical Cardiology, the American College of Chest Physicians and the American College of Cardiology. He is a diplomat of the American Board of Internal Medicine with certification in the subspecialties of cardiovascular diseases and advanced heart failure and transplantation. Dr. Benza currently holds administrative positions in the Pulmonary Vascular Research Institute and the International Society of Heart and Lung Transplantation and is the former treasurer of that society. He served on President Barak Obama’s Advisory Committee on Organ Transplantation (ACOT) in the Health Resources and Services Administration for 4 years and was knighted in 2015 by his Royal Highness Vittorio Emanuele of Italy for his philanthropic work in patients with pulmonary arterial hypertension and was admitted to the Association of University Cardiologists. He sits on multiple journal editorial committees and is the Steering Committee Chair for several industry trials in PAH. His primary clinical interests are the evaluation and treatment of advanced congestive heart failure, cardiac transplantation, and pulmonary arterial hypertension (PAH). He participates in major clinical studies of new therapies for the treatment of heart failure, mechanical support, and pulmonary hypertension. Dr. Benza is a funded investigator for the National Institutes of Health and the American Heart Association for his work in pulmonary arterial hypertension focusing on risk stratification, pharmacogenomics and new device therapies for this disease state. About TX45, a long-acting Fc-relaxin fusion protein TX45 is an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti-fibrotic and anti-inflammatory activity. In normal human physiology, relaxin is upregulated during pregnancy where it exerts vasodilative effects, reduces systemic and pulmonary vascular resistance and increases cardiac output to accommodate the increased demand for oxygen and nutrients from the developing fetus. Relaxin also exerts anti-fibrotic effects on pelvic ligaments to facilitate delivery of the baby. About Group 2 Pulmonary Hypertension in HFpEF The World Health Organization has defined five groups of pulmonary hypertension (“PH”). Tectonic is focused on the Group 2 subtype, a condition that develops due to left-sided heart disease, specifically pulmonary hypertension secondary to left heart failure with preserved ejection fraction (“PH-HFpEF”). In patients with PH-HFpEF, chronic heart failure leads to increased blood pressure in the pulmonary arteries, exerting severe strain on the right side of the heart, which adapts poorly to the increased pressure. This increased pulmonary pressure gradually causes worsening exercise capacity, shortness of breath and right-sided heart failure which can lead to death. Although several Group 1 PH (Pulmonary Arterial Hypertension, PAH) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment. About Tectonic Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODeTM (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include statements regarding: the design, objectives, initiation, timing, progress and results of clinical trials of Tectonic’s product candidates, including the ongoing Phase 1b and Phase 2 clinical trials for TX45 in Group 2 PH-HFpEF; and the potential properties and benefits of TX45. These forward-looking statements are based on Tectonic’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Tectonic’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on Tectonic’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Tectonic’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Tectonic’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in Tectonic’s quarterly report on Form 10-Q filed with the SEC on November 12, 2024, and in other filings that Tectonic makes and will make with the SEC in the future. Tectonic expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit www.tectonictx.com and follow on LinkedIn . Source: Tectonic TherapeuticOilfield services provider Flowco shows revenue surge in US IPO filing

The AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . DELAND, Fla. (AP) — Tyler Johnson scored seven of his 26 points in overtime to lead Mercer to an 89-83 victory over Stetson on Sunday. Johnson had five rebounds and three steals for the Bears (5-4). Alex Holt added 23 points and seven rebounds. Ahmad Robinson scored 16. Robinson made the first of two free throws with 1 second left to force overtime tied at 73. The Hatters (1-8) were led in scoring by Jordan Wood, who finished with 23 points and two blocks. Josh Massey added 22 points and eight rebounds. Mehki also had 14 points and six assists. The Hatters extended their losing streak to eight in a row. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

The Guns of Lautoka

Former NC State WR KC Concepcion transferring to Texas A&M